Automate Your Wheel Strategy on INSM
With Tiblio's Option Bot, you can configure your own wheel strategy including INSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INSM
- Rev/Share 2.8386
- Book/Share 3.459
- PB 45.9754
- Debt/Equity 0.0619
- CurrentRatio 3.8266
- ROIC -0.6507
- MktCap 33916879775.0
- FreeCF/Share -4.6695
- PFCF -33.9993
- PE -26.6098
- Debt/Assets 0.0202
- DivYield 0
- ROE -1.6836
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INSM | Barclays | -- | Overweight | -- | $231 | Jan. 28, 2026 |
| Initiation | INSM | Roth Capital | -- | Buy | -- | $212 | Jan. 23, 2026 |
| Resumed | INSM | Truist | -- | Buy | -- | $202 | Dec. 19, 2025 |
| Initiation | INSM | Rothschild & Co Redburn | -- | Buy | -- | $263 | Dec. 4, 2025 |
| Resumed | INSM | Cantor Fitzgerald | -- | Overweight | -- | $192 | Oct. 28, 2025 |
| Initiation | INSM | Wells Fargo | -- | Overweight | -- | $171 | Oct. 20, 2025 |
| Initiation | INSM | William Blair | -- | Outperform | -- | -- | Aug. 20, 2025 |
| Downgrade | INSM | Morgan Stanley | Overweight | Equal Weight | -- | $126 | Aug. 13, 2025 |
| Initiation | INSM | Jefferies | -- | Buy | -- | $105 | May 13, 2025 |
| Initiation | INSM | RBC Capital Mkts | -- | Outperform | -- | $100 | Feb. 25, 2025 |
News
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.
Read More
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Insmed (INSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript
Read More
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Negative
Insmed (INSM) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.32 per share a year ago.
Read More
What to Expect From These Drug/Biotech Players This Earnings Season?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Neutral
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Read More
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Neutral
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (Raytheon), Capital One and Somnigroup. In addition to Insmed and BAE, we also added to L3Harris, a global aerospace and defense company.
Read More
Artisan Small Cap Fund Q4 2025 Portfolio Activity
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Neutral
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Published: January 22, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Published: January 01, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
Read More
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
Published: December 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
Read More
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
Published: November 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Read More
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Read More
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — — BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J. , Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment …
Read More
Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated ( INSM ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Thanks for joining the session -- fireside session was Insmed and my name is Clara Dong, one of the biotech analysts here.
Read More
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
Read More
Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated ( INSM ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Roger Adsett - Chief Operating Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Ritu Baral - TD Cowen, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jason Zemansky - BofA Securities, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Vamil Divan - Guggenheim Securities, LLC, Research …
Read More
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Insmed (INSM) came out with a quarterly loss of $1.75 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.27 per share a year ago.
Read More
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
Read More
Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
Insmed remains a compelling biotech trade after Brinsupri's FDA approval for NCFB, with strong de-risking and significant market potential. Brinsupri's aggressive pricing and broad label could drive peak sales above $5 billion, with additional pipeline assets offering upside. M&A speculation is high, with INSM seen as a prime acquisition target for major pharma companies like GSK, AZN, and NVS.
Read More
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm honored to have Will Lewis here, CEO of Insmed. Before we get started, though, I have to read some brief disclosures.
Read More
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.
Read More
About Insmed Incorporated (INSM)
- IPO Date 2000-06-01
- Website https://www.insmed.com
- Industry Biotechnology
- CEO William H. Lewis
- Employees 1271